Inflammatory bowel diseases belong to a group of chronic inflammatory disorders. These disorders can be treated by using biological therapy, such as TNF inhibitors – TNF-α blockers, which have been in use for several years. Despite growing expertise in using these drugs, the molecular mechanisms which determine their efficiency are still not fully explained. In this paper we present the current status of this topic and we try to indicate its clinical implications